Andrew Alexis

6.4k total citations · 1 hit paper
189 papers, 3.9k citations indexed

About

Andrew Alexis is a scholar working on Dermatology, Immunology and Immunology and Allergy. According to data from OpenAlex, Andrew Alexis has authored 189 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Dermatology, 34 papers in Immunology and 32 papers in Immunology and Allergy. Recurrent topics in Andrew Alexis's work include Dermatology and Skin Diseases (72 papers), Acne and Rosacea Treatments and Effects (68 papers) and Skin Protection and Aging (49 papers). Andrew Alexis is often cited by papers focused on Dermatology and Skin Diseases (72 papers), Acne and Rosacea Treatments and Effects (68 papers) and Skin Protection and Aging (49 papers). Andrew Alexis collaborates with scholars based in United States, Canada and United Kingdom. Andrew Alexis's co-authors include Bridget Kaufman, Susan C. Taylor, Emma Guttman‐Yassky, Jonathan I. Silverberg, Valerie Callender, Brigitte Dréno, Bruce Strober, Seemal R. Desai, Marina Marinovich and Animesh A. Sinha and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Journal of Investigative Dermatology and Journal of the American Academy of Dermatology.

In The Last Decade

Andrew Alexis

173 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*

2020 213 citations Jonathan I. Silverberg, D. Toth et al. British Journal of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Alexis United States	31	3.0k	943	582	529	482	189	3.9k
Hei Sung Kim South Korea	33	2.0k 0.7×	288 0.3×	365 0.6×	279 0.5×	392 0.8×	227	3.8k
David J. Gawkrodger United Kingdom	44	2.7k 0.9×	1.1k 1.2×	1.5k 2.6×	1.2k 2.3×	294 0.6×	168	5.3k
Matthew Zirwas United States	32	2.7k 0.9×	1.0k 1.1×	137 0.2×	316 0.6×	199 0.4×	168	3.7k
Alireza Firooz Iran	37	1.7k 0.6×	232 0.2×	468 0.8×	332 0.6×	190 0.4×	231	4.1k
Giuseppe Monfrecola Italy	35	2.2k 0.7×	217 0.2×	597 1.0×	436 0.8×	215 0.4×	129	3.4k
Cataldo Patruno Italy	31	2.1k 0.7×	818 0.9×	96 0.2×	619 1.2×	382 0.8×	216	3.0k
Fabio Ayala Italy	34	1.8k 0.6×	507 0.5×	148 0.3×	1.2k 2.3×	351 0.7×	196	3.5k
Magnus Lindberg Sweden	34	2.2k 0.7×	1.0k 1.1×	211 0.4×	286 0.5×	372 0.8×	127	3.4k
Vivian Y. Shi United States	32	2.3k 0.8×	738 0.8×	89 0.2×	271 0.5×	322 0.7×	250	3.2k
Ali Alikhan United States	27	2.4k 0.8×	260 0.3×	684 1.2×	370 0.7×	174 0.4×	91	3.7k

Countries citing papers authored by Andrew Alexis

Since Specialization

Citations

This map shows the geographic impact of Andrew Alexis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Alexis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Alexis more than expected).

Fields of papers citing papers by Andrew Alexis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Alexis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Alexis. The network helps show where Andrew Alexis may publish in the future.

Co-authorship network of co-authors of Andrew Alexis

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Alexis. A scholar is included among the top collaborators of Andrew Alexis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Alexis. Andrew Alexis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lim, Henry W., Chengfeng Zhang, Ncoza C. Dlova, et al.. (2025). International Expert Consensus on Knowledge Gaps in Care for Dermatologic Disorders in Skin of Color. International Journal of Dermatology. 65(1). 41–56. 1 indexed citations

Alexis, Andrew, Leon Kircik, Raj Chovatiya, et al.. (2025). Tapinarof Cream for Adults and Children with Atopic Dermatitis—Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials. Dermatology and Therapy. 15(9). 2667–2682.

Lim, Henry W., Chengfeng Zhang, Ncoza C. Dlova, et al.. (2025). International Expert Consensus on Defining Skin of Color and Delivering Equitable Dermatologic Care. International Journal of Dermatology. 65(1). 28–40. 1 indexed citations

Bissonnette, Robert, Linda Stein Gold, Leon Kircik, et al.. (2024). Skin Clearance, Treatment Response Off-therapy, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 8(6). s460–s460. 3 indexed citations

Strober, Bruce, Andrew Blauvelt, Richard B. Warren, et al.. (2024). Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2). Journal of the European Academy of Dermatology and Venereology. 38(8). 1543–1554. 27 indexed citations

Kaufman, Bridget, et al.. (2024). Efficacy and Safety of Secukinumab in the Treatment of Psoriasis in Patients with Skin Phototypes IV to VI. Journal of Drugs in Dermatology. 23(8). 600–606. 1 indexed citations

Alexis, Andrew, Amy McMichael, Neelam A. Vashi, et al.. (2024). Improving Diversity in a Novel Psoriasis Study. JAMA Dermatology. 161(3). 256–256. 5 indexed citations

Alexis, Andrew, et al.. (2024). Diagnosis of Allergic Dermatoses in Skin of Color. Current Allergy and Asthma Reports. 24(6). 317–322. 3 indexed citations

Blauvelt, Andrew, David M. Pariser, Stephen K. Tyring, et al.. (2023). Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. Journal of Dermatological Science. 109(1). 12–21. 11 indexed citations

10.

Layton, Alison, Andrew Alexis, Hilary Baldwin, et al.. (2023). The Personalized Acne Treatment Tool — Recommendations to facilitate a patient-centered approach to acne management from the Personalizing Acne: Consensus of Experts. JAAD International. 12. 60–69. 11 indexed citations

11.

Schachner, Lawrence A., Andrew Alexis, Anneke Andriessen, et al.. (2023). Insights into acne and the skin barrier: Optimizing treatment regimens with ceramide‐containing skincare. Journal of Cosmetic Dermatology. 22(11). 2902–2909. 15 indexed citations

12.

Takeshita, Junko, Matthias Augustin, E.M.G.J. de Jong, et al.. (2022). Health-Related QOL Differs by Race/Ethnicity in North American Patients with Psoriasis: Results from PSOLAR. Journal of Investigative Dermatology. 142(9). 2528–2531.e3. 5 indexed citations

13.

Baldwin, Hilary, Andrew Alexis, Anneke Andriessen, et al.. (2021). Evidence of Barrier Deficiency in Rosacea and the Importance of Integrating OTC Skincare Products into Treatment Regimens. Journal of Drugs in Dermatology. 20(4). 384–392. 11 indexed citations

14.

Alexis, Andrew, Heather Woolery‐Lloyd, Kiyanna Williams, et al.. (2021). Racial/Ethnic Variations in Skin Barrier: Implications for Skin Care Recommendations in Skin of Color. Journal of Drugs in Dermatology. 20(9). 932–938. 27 indexed citations

15.

Callender, Valerie, Hilary Baldwin, Fran Cook-Bolden, et al.. (2021). Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice. American Journal of Clinical Dermatology. 23(1). 69–81. 43 indexed citations

16.

Silverberg, Jonathan I., D. Toth, Thomas Bieber, et al.. (2020). Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*. British Journal of Dermatology. 184(3). 450–463. 213 indexed citations breakdown →

17.

Alexis, Andrew, et al.. (2020). Efficacy, safety, and tolerability of halobetasol propionate 0.01%⇓tazarotene 0.045% lotion for moderate to severe plaque psoriasis in the hispanic population: Post hoc analysis py. Cutis. 105(3). 150–155. 1 indexed citations

18.

Kaufman, Bridget, Emma Guttman‐Yassky, & Andrew Alexis. (2018). Atopic dermatitis in diverse racial and ethnic groups—Variations in epidemiology, genetics, clinical presentation and treatment. Experimental Dermatology. 27(4). 340–357. 235 indexed citations

19.

Pavel, Ana B., Jacob W. Glickman, Tom C. Chan, et al.. (2018). Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation. Annals of Allergy Asthma & Immunology. 122(1). 99–110.e6. 155 indexed citations

20.

Alexis, Andrew, et al.. (2004). Alopecia areata: autoimmune basis of hair loss.. PubMed. 14(6). 364–70. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact